ClinicalTrials.gg

Program

pelabresib

Also written as “Pelabresib” and “CPI-0610”.

In Novartis's pipeline, BET inhibitor. Its studies are mostly in Primary Myelofibrosis · Hematologic Neoplasms · Lymphoma, Follicular · Lymphoma · Multiple Myeloma, led by 2 companies.

Furthest: phase 3, since Oct 20, 202011 company-led studies, 7 open or runningNext primary completion: Mar 9, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis77 open or runningphase 3since Oct 20, 2020Oct 20, 2020Mar 9, 2028phase 1 · NCT07340190
Constellation Pharmaceuticals40 open or runningphase 2since Jun 5, 2014Sep 10, 2013none ahead
  • Named in Novartis’s own pipeline as DAK539 (pelabresib), phase 4, as of Nov 16, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 10, 2013First study: phase 1 study in LymphomaNew to Constellation PharmaceuticalsConstellation Pharmaceuticals · NCT01949883 · 64 enrolled
  2. May 28, 2014Phase 1 study in Multiple MyelomaConstellation Pharmaceuticals · NCT02157636 · 30 enrolled
  3. Jun 5, 2014Phase 2 study in Primary MyelofibrosisConstellation Pharmaceuticals · NCT02158858 · 336 enrolled · United States, Belgium, Canada and more
  4. Oct 20, 2020Novartis's first study: phase 3 study in Primary MyelofibrosisNew to NovartisNovartis · NCT04603495 · 430 enrolled · United States, Australia, Austria and more
  5. May 5, 2022Phase 1 study in Hematologic NeoplasmsConstellation Pharmaceuticals · NCT05391022 · 35 enrolled · United States, Georgia, Spain
  6. May 2, 2024Phase 3 study in Hematologic NeoplasmsNovartis · NCT06401356 · 50 planned · United States, Belgium, Italy and more
  7. Jan 6, 20263 phase 1 studiesNovartis · NCT07340190, NCT07340138, NCT07422610
  8. Jan 15, 2026Phase 3 study in Primary MyelofibrosisNovartis · NCT07357727 · 460 planned · United States, Argentina, Australia and more
  9. Aug 18, 2026Phase 1 study in Healthy ParticipantsNovartis · NCT07783503 · 30 planned · United Kingdom
  10. Nov 12, 2026Primary completion moved from 2027-06-02 to 2029-12-31Date moved laterphase 3 · +31 months · NCT06401356

Ahead

  1. Nov 13, 2026Primary completion: phase 1 study in Healthy ParticipantsNovartis · NCT07783503
  2. Mar 9, 2028Primary completion: phase 1 study in Advanced MalignanciesNovartis · NCT07340190
  3. May 17, 2028Primary completion: phase 3 study in Primary MyelofibrosisNovartis · NCT07357727
  4. Jun 28, 2028Primary completion: phase 1 study in Lymphoma, FollicularNovartis · NCT07422610

TargetBeta

“BET inhibitor”the company's pipeline, read by Claude · source
“The hydrated form of pelabresib, a small molecule inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, pelabresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby prevent…”NCIt, read by Claude
“Bromodomain and extra-terminal motif (BET) inhibitor”ChEMBL 37, by rule

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07783503Healthy Participants · United Kingdom1RecruitingNovartisNov 13, 202630
NCT07422610Lymphoma, Follicular · France, Italy, Spain and more1RecruitingNovartisJun 28, 202824
NCT07357727Primary Myelofibrosis · United States, Argentina, Australia and more3RecruitingNovartisMay 17, 2028460
NCT07340190Advanced Malignancies · France, Italy, Spain1RecruitingNovartisMar 9, 202824
NCT07340138Primary Myelofibrosis · Japan1Active, not recruitingNovartisJul 23, 20263
NCT06401356Hematologic Neoplasms · United States, Belgium, Italy and more3RecruitingNovartisDec 31, 202950
NCT05391022Hematologic Neoplasms · United States, Georgia, Spain1CompletedConstellation PharmaceuticalsMar 8, 202335
NCT04603495Primary Myelofibrosis · United States, Australia, Austria and more3Active, not recruitingNovartisAug 23, 2023430
NCT02158858Primary Myelofibrosis · United States, Belgium, Canada and more2CompletedConstellation PharmaceuticalsJan 9, 2025336
NCT02157636Multiple Myeloma1CompletedConstellation PharmaceuticalsNov 8, 201630
NCT01949883Lymphoma1CompletedConstellation PharmaceuticalsDec 20, 201764

How it is read

Names in the registry

  • “Pelabresib”, 7 entries
  • “pelabresib”, 2 entries
  • “CPI-0610”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.